Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

450960

Sigma-Aldrich

Lutetium(III) chloride

anhydrous, powder, 99.99% trace metals basis

Sinonimo/i:

Lutetium chloride, Lutetium trichloride

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula condensata:
LuCl3
Numero CAS:
10099-66-8
Peso molecolare:
281.33
Numero CE:
233-240-1
Numero MDL:
MFCD00011099
Codice UNSPSC:
12352302
ID PubChem:
24868595
NACRES:
NA.23

Grado

anhydrous

Livello qualitativo

100

Saggio

99.99% trace metals basis

Forma fisica

powder

Impiego in reazioni chimiche

reagent type: catalyst
core: lutetium

Impurezze

≤150.0 ppm Trace Rare Earth Analysis

Punto di fusione

905 °C (lit.)

Densità

3.98 g/mL at 25 °C (lit.)

Stringa SMILE

Cl[Lu](Cl)Cl

InChI

1S/3ClH.Lu/h3*1H;/q;;;+3/p-3
AEDROEGYZIARPU-UHFFFAOYSA-K

Applicazioni

Lutetium(III) chloride can be used:
  • As a precursor to synthesize chiral bridged lutetium catalyst for asymmetric hydroamination.
  • As a starting material to prepare doped lutetium oxide nanophosphors.
  • To fabricate scintillation detectors such as lutetium aluminum garnet (LuAG).

Accessorio

N° Catalogo
Descrizione
Determinazione del prezzo

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Gloves

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
MKCB0960V
MKBV8849V
MKBR4789V
MKAA0295
MKBQ5281V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Lutetium (III) oxide 99.99% trace metals basis

Sigma-Aldrich

203661

Lutetium (III) oxide

Ytterbium(III) chloride anhydrous, powder, 99.9%

Sigma-Aldrich

439614

Ytterbium(III) chloride

Holmium(III) chloride anhydrous, powder, 99.9% trace metals basis

Sigma-Aldrich

450901

Holmium(III) chloride

Yttrium(III) chloride AnhydroBeads™, −10 mesh, 99.99% trace metals basis

Sigma-Aldrich

450103

Yttrium(III) chloride

Lanthanum(III) bromide AnhydroBeads™, −10 mesh, ≥99.99% trace metals basis

Sigma-Aldrich

449822

Lanthanum(III) bromide

Lutetium (III) oxide 99.9% trace metals basis

Sigma-Aldrich

289191

Lutetium (III) oxide

Sanjay Kumar Saxena et al.
Cancer biotherapy & radiopharmaceuticals, 32(10), 364-370 (2017-12-22)
The primary objective of this investigation is the development of a strategy for the synthesis of polyhydroxamic acid (PHA)-grafted cellulose film, its characterization, and evaluation of its usefulness for the preparation of
Usha Pandey et al.
Cancer biotherapy & radiopharmaceuticals, 34(5), 306-315 (2019-06-13)
Background: Transarterial radioembolization (TARE) represents an effective targeted therapeutic option for hepatocellular carcinoma (HCC), a cancer with high mortality
Ana Santidrián et al.
Physical chemistry chemical physics : PCCP, 22(18), 10063-10075 (2020-04-28)
In the present work, the effect of doping on electronic properties in bulk purified and filled arc-discharge single-walled carbon nanotubes samples is studied for the first time by in situ Raman spectroelectrochemical method. A major challenge to turn the potential
Raffaella Rossin et al.
Molecular pharmaceutics, 11(9), 3090-3096 (2014-08-01)
Radioimmunotherapy (RIT) of solid tumors is hampered by low tumor-to-nontumor (T/NT) ratios of the radiolabeled monoclonal antibodies resulting in low tumor doses in patients. Pretargeting technologies can improve the effectiveness of RIT in cancer therapy by increasing this ratio. We
Sander M J van Duijnhoven et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 56(9), 1422-1428 (2015-07-15)
Radioimmunotherapy and nuclear imaging (immuno-PET/SPECT) of cancer with radiometal-labeled antibody fragments or peptides is hampered by low tumor-to-kidney ratios because of high renal radiometal retention. Therefore, we developed and evaluated a pretargeting strategy using click chemistry in vivo to reduce
Visualizza tutti i documenti correlati

Articoli

The Rare Earth Crisis—The Supply/Demand Situation for 2010–2015

The rare earth elements impact nearly everyone in the world. All of the people living in advanced technological countries and almost all those living in third world countries utilize the rare earths in their everyday living—the car that one drives (gasoline is refined from oil using rare earth catalysts and catalytic converters reduce the polluting emissions from the automotive exhaust), watching the news on TV (the red and green colors in TV screens), the telephones and computers we use to communicate (the permanent magnets in speakers and disc drives), just to name a few examples.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.